Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aleve “Doctor Recommended” Ad Claim Has No “Reasonable Basis” – NAD

This article was originally published in The Tan Sheet

Executive Summary

Bayer Consumer Care should modify TV ads comparing the company's Aleve analgesic with McNeil Consumer and Specialty Pharmaceuticals' Tylenol "to avoid conveying a 'doctor recommended message,'" the National Advertising Division of the Council of Better Business Bureaus says

You may also be interested in...



McNeil, Bayer Aleve Ad Dispute Heats Up With Federal Lawsuit

McNeil Consumer & Specialty Pharmaceuticals' has taken its dispute with Bayer Consumer Care over advertising for Aleve to court, after a NAD decision apparently failed to resolve the conflict

Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court

A recent British Medical Journal study does not support McNeil Consumer & Specialty Pharmaceuticals' advertising claims that 81 mg aspirin "is just as effective as 325 mg in reducing the risk of recurrent heart attacks," Bayer says in a lawsuit filed in New York federal court April 25

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS096359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel